Amyloidosis biologic to be developed by GSK and UCL

Researchers from Pentraxin Therapeutics (University College, London’s [UCL] spinout commercialisation company) and GlaxoSmithKline (GSK) are to work together to develop a new treatment for amyloidosis. The researchers will collaborate to transfer the drug from animal testing into human trials.

The treatment, which is the first of its kind, combines a small molecule (CHPHC) with an antibody that seeks out amyloid deposits. In studies in mice, this combination resulted in the rapid clearance of amyloid deposits.